ArticleBMC geriatrics2026
From real-world pharmacovigilance data to clinical practice: a geriatric-specific predictive model for immune-related adverse events in lung cancer based on routine clinical indicators.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitors frequently cause severe immune-related adverse events (irAEs) in elderly lung cancer patients due to age-related immune decline. This study conducted a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) to investigate the safety profile in this vulnerable population and explore influencing factors of irAEs based on retrospective real-world data.
methodsWe obtained adverse event reports for elderly lung cancer patients (≥ 65 years) treated with FDA-approved immune checkpoint inhibitors from the FAERS database, covering the period from the third quarter of 2014 to the third quarter of 2025. The reporting odds ratio was used to identify significant adverse event signals. A retrospective single-center cohort of 250 patients was used to develop a random forest model for predicting grade ≥ 2 irAEs.
resultsAnalysis of 19,681 reports revealed a higher reporting proportion of fatal outcomes in elderly patients (ROR = 1.09, 95% CI: 1.04-1.14, p < 0.001). In the development cohort (median age 71), 36.8% developed grade ≥ 2 irAEs. The model incorporating Geriatric-8, platelet-to-lymphocyte ratio, and body mass index showed moderate discriminative performance (AUC = 0.740; 95% CI: 0.705-0.775) and good calibration (Brier score = 0.18). SHAP analysis revealed that lower Geriatric-8 scores and higher platelet-to-lymphocyte ratio increased irAE risk, with body mass index showing a U-shaped association.
conclusionsElderly lung cancer patients face a higher reporting proportion of severe and fatal adverse events during immune checkpoint inhibitor treatment, based on FAERS data. Geriatric-8, platelet-to-lymphocyte ratio, and body mass index were identified as potential clinical predictors for irAEs in this population, offering a practical tool for risk assessment and management pending external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.